Pacira Biosciences Inc

Pacira Biosciences Inc has a market capitalization of $923.89 million and a price-to-earnings ratio of 131.35, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 1.33, suggesting that the market values the company slightly above its book value. The enterprise value to EBITDA ratio is 157.82, which is significantly high, reflecting a premium valuation relative to its earnings before interest, taxes, depreciation, and amortization. In terms of profitability, Pacira Biosciences Inc has a return on equity of 1.01% and a return on assets of 0.56%, both of which are below the industry median for pharmaceutical companies. The company's net income is $7.03 million, and its operating income is $7.21 million, indicating a narrow profit margin. The gross profit margin is 79.4%, which is relatively high but does not fully translate into strong net profitability. The company's revenue is concentrated in the United States, with no significant international operations disclosed. The financial data does not provide segment-specific revenue details, but the company's primary focus is on pain management products. The lack of geographic diversification and segment breakdown suggests a potential concentration risk. Looking at the growth trajectory, Pacira Biosciences Inc's revenue for the latest period is $726.41 million. The company's outlook for the current fiscal year is not explicitly provided, but the high price-to-earnings ratio suggests that investors are betting on future growth. The company's free cash flow is $82.72 million, which provides some flexibility for reinvestment or debt reduction. The risk assessment for Pacira Biosciences Inc indicates a medium liquidity risk and a low dilution risk. The company has a current ratio of 4.54, which is strong, but its net cash position is negative after subtracting total debt. The debt-to-equity ratio is 0.54, indicating a moderate level of leverage. The company's liquidity position is supported by $158.55 million in cash and equivalents. Recent events and filings do not show any significant changes in the company's financial structure or strategic direction. The company's recent financial performance and analyst estimates suggest a mixed outlook, with a mean price target of $29.00 and a median price target of $27.00. The mean recommendation from analysts is 2.43, indicating a generally positive but cautious outlook.